GSK seeks U.S. approval for shingles vaccine Shingrix
LONDON, Oct (HKSE: 3366-OL.HK - news) 24 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) said on Monday it had filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential blockbuster a step closer to market.
Shingrix is viewed by analysts as among the British drugmaker's most promising experimental products, since it has shown greater protection among older recipients than Merck (Jakarta: 28586808.JK - news) & Co's rival shot Zostavax.
GSK said it planned to file Shingrix for European and Canadian approval before the end of this year, with Japan following in 2017.
(Reporting by Ben Hirschler; Editing by Susan Fenton)